Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2 Market Overview
- Background: Genetic Material
- RNA Interference Overview
- RNA Interference: Mechanism of Action
- Initiation Phase
- Effector Phase
- Small Interfering RNAs (siRNAs)
- MicroRNAs (miRNAs)
- Small Hairpin RNAs (shRNAs)
Chapter 3 Market Dynamics
- Global Market Dynamics
- Market Drivers
- Increasing Prevalence of Chronic Disease
- Increasing Approval of RNAi Products
- Advancements in RNAi Delivery Systems
- Increasing Strategic Initiatives
- Convenient Dosing
- Market Restraints
- High Treatment Costs
- Lack of Awareness
- Market Opportunities
- Expansion of Disease Targets
- Combination Therapies
- Untapped Genetic Targets
Chapter 4 Emerging Technologies and Developments
- Therapeutics
- Diagnostics
- Circulating miRNA Diagnostics for Non-invasive Health Monitoring
- Agriculture
Chapter 6 Patent Analysis
Chapter 7 Market Segmentation Analysis
- Segmentation Breakdown
- Overview
- Market Analysis by Technology
- Therapeutics
- RNAi Therapeutics Market, by Region
- RNAi Therapeutics Market, by Therapeutic Area
- RNAi Therapeutics Market, by Delivery Method
- Diagnostics
- Reagents and Tools
- Agriculture
- Geographic Breakdown
- Market Analysis by Region
- North America
- Europe
- Emerging Markets
Chapter 8 Competitive Intelligence
- Strategic Initiatives
- Competitive Analysis
Chapter 9 Sustainability in RNAi Technology Market: An ESG Perspective
- Introduction to ESG
- Sustainability in RNAi Technology Industry: An ESG Perspective
- Environmental Initiatives
- Social Initiatives
- Governance Initiatives
- Case Study
- Concluding Remarks
List of Tables
Summary Table: Global Market for RNAi Technology, by Technology Type, Through 2029
Table 1: Projected Number of Adults 50 Years and Older with =1 Chronic Condition in the U.S., 2020-2050
Table 2: Cost Comparison of siRNA-approved Drugs and Alternative Therapies
Table 3: List of Selected Pipeline Molecules
Table 4: Selected Patents for RNAi Technology, Published in 2021
Table 5: Selected Patents for RNAi Technology, Published in 2022
Table 6: Selected Patents for RNAi Technology, Published in 2023
Table 7: Selected Patents for RNAi Technology, Published January to April 2024
Table 8: Global Market for RNAi Technology, by Technology Type, Through 2029
Table 9: RNAi Approved Drugs List
Table 10: Global Market for RNAi Therapeutics, by Region, Through 2029
Table 11: Global Market for RNAi Therapeutics, by Therapeutic Area, Through 2029
Table 12: Global Market for RNAi Therapeutics, by Delivery Method, Through 2029
Table 13: miRNA-based Diagnostic Tools Available in Clinical Settings
Table 14: Global Market for RNAi Diagnostics, by Region, Through 2029
Table 15: Global Market for RNAi Reagents and Tools, by Type, Through 2029
Table 16: Global Market for RNAi Reagents and Tools, by Region, Through 2029
Table 17: Global Market for RNAi Research Tools and Constructs, by Region, Through 2029
Table 18: Global Market for RNAi Reagents, by Region, Through 2029
Table 19: Global Market for RNAi Agriculture, by Region, Through 2029
Table 20: Global Market for RNAi Technology, by Region, Through 2029
Table 21: Strategic Initiatives in Global RNAi Technology Market, 2020-2024
Table 22: Global Rankings of Top RNAi Reagents and Tools Manufacturers, 2022
Table 23: Key Focus Areas in ESG Metrices
Table 24: Environmental Initiatives, by Various RNAi Technology Companies
Table 25: ESG Rankings for Companies in the RNAi Technology Market, 2023
Table 26: Alnylam’s ESG initiatives
Table 27: Glossary of Terms Used in This Report
Table 28: Report Information Sources
Table 29: Alnylam Pharmaceuticals Inc.: Company Snapshot
Table 30: Alnylam Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 31: Alnylam Pharmaceuticals Inc.: Product Portfolio
Table 32: Alnylam Pharmaceuticals Inc.: News/Key Developments, 2023
Table 33: Arrowhead Pharmaceuticals Inc.: Company Snapshot
Table 34: Arrowhead Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 35: Arrowhead Pharmaceuticals Inc.: News/Key Developments, 2021-2024
Table 36: Arbutus BioPharma Corp.: Company Snapshot
Table 37: Arbutus Biopharma Corp.: Financial Performance, FY 2022 and 2023
Table 38: Arbutus BioPharma Corp.: News/Key Developments, 2021-2023
Table 39: Bayer AG: Company Snapshot
Table 40: Bayer AG: Financial Performance, FY 2022 and 2023
Table 41: Bayer AG: Product Portfolio
Table 42: Bayer AG: News/Key Developments, 2023
Table 43: Merck KGaA: Company Snapshot
Table 44: Merck KGaA: Financial Performance, FY 2022 and 2023
Table 45: Merck KGaA.: Product Portfolio
Table 46: Merck KGaA: News/Key Developments, 2021-2024
Table 47: Novartis AG: Company Snapshot
Table 48: Novartis AG: Financial Performance, FY 2022 and 2023
Table 49: Novartis AG: Product Portfolio
Table 50: Novartis AG: News/Key Developments, 2020-2024
Table 51: Novo Nordisk A/S: Company Snapshot
Table 52: Novo Nordisk A/S: Financial Performance, FY 2022 and 2023
Table 53: Novo Nordisk A/S: Product Portfolio
Table 54: Novo Nordisk A/S: News/Key Developments, 2021-2023
Table 55: OliX Pharmaceuticals Inc.: Company Snapshot
Table 56: OliX Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 57: OliX Pharmaceuticals Inc.: News/Key Developments, 2019-2023
Table 58: Qiagen: Company Snapshot
Table 59: Qiagen: Financial Performance, FY 2022 and 2023
Table 60: Qiagen: Product Portfolio
Table 61: Qiagen: News/Key Developments, 2023
Table 62: Revvity Inc.: Company Snapshot
Table 63: Revvity Inc.: Financial Performance, FY 2022 and 2023
Table 64: Revvity Inc.: Product Portfolio
Table 65: Revvity Inc.: News/Key Developments, 2023 and 2024
Table 66: Silence Therapeutics: Company Snapshot
Table 67: Silence Therapeutics: Financial Performance, FY 2022 and 2023
Table 68: Silence Therapeutics: News/Key Developments, 2022 and 2023
Table 69: Sirnaomics: Company Snapshot
Table 70: Sirnaomics: Financial Performance, FY 2022 and 2023
Table 71: Sirnaomics: News/Key Developments, 2023
Table 72: Sylentis S.A.: Company Snapshot
Table 73: Sylentis S.A.: News/Key Developments, 2023
Table 74: Switch Therapeutics: Company Snapshot
Table 75: Thermo Fisher Scientific Inc.: Company Snapshot
Table 76: Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 77: Thermo Fisher Scientific Inc.: Product Portfolio
Table 78: Thermo Fisher Scientific Inc.: News/Key Developments, 2021-2023
List of Figures
Summary Figure: Global Market for RNAi Technology, by Technology Type, 2021-2029
Figure 1: RNAi Pathway
Figure 2: Market Dynamics of RNAi Technology
Figure 3: Tissues Targeted by RNAi Therapeutics
Figure 4: Patents Documented Over Time, 2010-April 2024
Figure 5: Global Market for RNAi Technology, by Technology Type, 2021-2029
Figure 6: Global Market Shares of RNAi Technology, by Technology Type, 2023
Figure 7: RNAi Therapeutics Timeline, 1998-2023
Figure 8: Global Market for RNAi Therapeutics, by Region, 2021-2029
Figure 9: Global Market for RNAi Therapeutics, by Therapeutic Area, 2021-2029
Figure 10: Global Market for RNAi Therapeutics, by Delivery Method, 2021-2029
Figure 11: MicroRNA (miRNA) Biomarkers in Various Cancers
Figure 12: Global Market for RNAi Diagnostics, by Region, 2021-2029
Figure 13: Global Market for RNAi Reagents and Tools, by Type, 2021-2029
Figure 14: Global Market for RNAi Reagents and Tools, by Region, 2021-2029
Figure 15: Global Market for RNAi Research Tools and Constructs, by Region, 2021-2029
Figure 16: Global Market for RNAi Reagents, by Region, 2021-2029
Figure 17: Global Market for RNAi Agriculture, by Region, 2021-2029
Figure 18: Global Market for RNAi Technology, by Region, 2021-2029
Figure 19: Global Market Shares of RNAi Technology, by Region, 2023
Figure 20: Global Market Shares of RNAi Technology, by Suppliers/Manufacturers, 2023
Figure 21: Research Communities’ Key Sustainable Practices in Research Laboratories
Figure 22: Alnylam Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
Figure 23: Alnylam Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023
Figure 24: Bayer AG: Revenue Share, by Business Unit, FY 2023
Figure 25: Bayer AG: Revenue Share, by Country/Region, FY 2023
Figure 26: Merck KGaA: Revenue Share, by Business Unit, FY 2023
Figure 27: Merck KGaA: Revenue Share, by Country/Region, FY 2023
Figure 28: Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 29: Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 30: Novo Nordisk A/S: Revenue Share, by Business Unit, FY 2023
Figure 31: Novo Nordisk A/S: Revenue Share, by Country/Region, FY 2023
Figure 32: Qiagen: Revenue Share, by Business Unit, FY 2023
Figure 33: Qiagen: Revenue Share, by Country/Region, FY 2023
Figure 34: Revvity Inc.: Revenue Share, by Business Unit, FY 2023
Figure 35: Revvity Inc.: Revenue Share, by Country/Region, FY 2023
Figure 36: Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2023
Figure 37: Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2023
